NASDAQ:CRBP

Corbus Pharmaceuticals Holdings Stock News

etoro logo Buy CRBP
*Your capital is at risk
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Artículo vía El Planteo. Mientras la industria del cannabis sigue avanzando, más y más compañías se mueven para conseguir que sus...
Oppenheimer analyst Leland Gershell reiterated a Buy rating on Alnylam Pharma (ALNY) today and set a price target of $140.00. The company's shares closed
Oppenheimer analyst Leland Gershell reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price
299 cannabis companies have securities that actively trade on the various stock exchanges in Canada & the U.S.within 11 categories based on their primary area of focus.
Equities research analysts expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to post $1.64 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates f
The Non-penny Pot Stock Index increased by 13.1%% this past week exceeding the 7.7% increase in the total cannabis sector of 319 stocks. 29 of the 36 eligible stocks in the NPSI went up, 2 remained un
Gainers The Flowr (OTC: FLWPF) shares closed up 18.98% at $0.44 NexTech AR Solns (OTC: NEXCF) shares closed up 19.26% at $1.12 Neptune Wellness Solns (NASDAQ: NEPT...
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ.Canadian medical marijuana producer Aphria Inc (NYSE: APH
Yuval Cohen became the CEO of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in 2014. This report will, first...
Corbus Pharmaceuticals (NASDAQ:CRBP) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Thursday, BidAskClub reports. CRBP has bee
In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Catalyst Pharma (CPRX), with a price target of $10.00. The
In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Catalyst Pharma ( CPRX – Research Report ), with a price target of $10.00 . The company’s shares closed
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains...
After Cowen & Co. and H.C. Wainwright gave X4 Pharmaceuticals (NASDAQ: XFOR) a Buy rating last month, the company received another Buy, this time from
After Cowen & Co. and H.C. Wainwright gave X4 Pharmaceuticals (NASDAQ: XFOR) a Buy rating last month, the company received
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE